




PHARMACEUTICAL 2019

BRISTOL MYERS SQUIBB CO
Rank 175 of 363





PHARMACEUTICAL 2019

BRISTOL MYERS SQUIBB CO Rank 175 of 363



The relative strengths and weaknesses of BRISTOL MYERS SQUIBB CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BRISTOL MYERS SQUIBB CO compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 95% points. The greatest weakness of BRISTOL MYERS SQUIBB CO is the variable Assets, Current, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 104%, being 68% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	17,160,000
Cost of Goods Sold	6,547,000
Intangible Assets	7,629,000
Liabilities, Current	10,654,000
Liabilities, Non-Current	6,694,000
Other Assets	5,170,000
Other Compr. Net Income	-183,000
Other Expenses	171,000
Other Liabilities	3,511,000
Other Net Income	0
Other Revenues	22,561,000
Property and Equipment	5,027,000
Research and Development	6,345,000
Selling, General and Administrative Expense	4,551,000

Output Variable	Value in 1000 USD
Assets	34,986,000
Liabilities	20,859,000
Expenses	17,614,000
Revenues	22,561,000
Stockholders Equity	14,127,000
Net Income	4,947,000
Comprehensive Net Income	4,855,500
Economic Capital Ratio	104%